



*Better health through
laboratory medicine.*

PEARLS OF LABORATORY MEDICINE

Patient Blood Management

Ryan A. Metcalf, MD, CQA(ASQ)

University of Utah and ARUP Laboratories

DOI:10.15428/CCTC.2019.316539



Patient Blood Management (PBM)

- What is it?
 - Rationally optimizing anemia and hemostasis
 - Goal of restricting (optimizing) blood component use
- Why do we care?
 - Blood transfusion = most common procedure¹
 - Top five most overused²
 - Standard of care³

Value = Quality / Cost

Decline in transfusions in US⁴


- 2008: ~15 million RBC units transfused
- 2015: 11.3 million RBC units transfused
- Likely due to implementation of PBM programs including evidence-based transfusion guidelines
 - Several large trials support a “restrictive” transfusion strategy



What might a PBM program encompass?

- Education program
- Optimize blood component use
- Diagnose and treat perioperative anemia
- Reduce/optimize blood loss in surgery and from lab draws

- Challenge: blood transfusion ordered by a variety of specialties and administered by a variety of health care staff



Project
Management

Red Blood Cell (RBC) Transfusion Trials Comparing Hemoglobin Thresholds⁵

Trial	Population	Participants (n)	Thresholds (hemoglobin)	Primary outcome
TRICC	Critical care	838	7 g/dL vs 10 g/dL	30d mortality 18.7% vs 23.3%, P=0.11
FOCUS	Hip fracture	2016	8 g/dL vs 10 g/dL	Death or inability to walk across room at 60d, 35.2% vs 34.7%, P=0.9
Villanueva et al.	Upper GI Hemorrhage	921	7 g/dL vs 9 g/dL	Mortality at 45d, 5% vs 9% P=0.02
TRISS	Septic Shock	998	7 g/dL vs 9 g/dL	90d mortality, 43% vs 45% P=0.44
TITRE2	Post-cardiac surgery	2003	7.5 g/dL vs 9 g/dL	Infection or ischemic event in 3mo, 35.1% vs 33.0% P=0.3
TRICS-III	Cardiac surgery	4860	7.5 g/dL vs 8.5 or 9.5 g/dL	Composite, 11.4% vs 12.5% P<0.001 for noninferiority

Treat the patient, not the laboratory value

- Indications for RBC transfusion
 - Significant acute hemorrhage
 - Significant signs/symptoms of anemia
- However, lab values (e.g. hemoglobin) do provide very useful information to help decide whether to transfuse or not



PBM strategies to reduce unnecessary transfusions

- Clinical decision support improves RBC usage⁶
 - Best practice alert (“pop-ups”) at computerized provider order entry
- RBC transfusion interventions reduce the proportion of patients transfused⁷
- Initiatives that successfully reduce RBC transfusion also reduce health care costs
 - RBC acquisition cost ~\$200
 - RBC total activity based cost ~\$800+

Indications for transfusion of other blood components

- **Platelets**
 - Bleeding prophylaxis (general): platelet count $<5-10\text{k/ul}$
 - Procedures/hemorrhage: paucity of evidence
- **Plasma**
 - Massive hemorrhage
 - Disseminated intravascular coagulation
 - Thrombotic thrombocytopenic purpura
 - Replacement of plasma constituent for which a more targeted therapy is not available
- **Cryoprecipitate** (contains fibrinogen, FVIII, vWF, FXIII)
 - Control bleeding associated with fibrinogen deficiency



Education program

- Materials: e.g. learning modules
- In-person: e.g. grand rounds
- Indications for transfusion, risks, evidence
- Develop hospital guidelines, protocols for specific clinical situations



Anemia Management⁸

- Preoperative
 - Screening: 3-4 weeks prior to elective surgery with expected major blood loss
 - Diagnose and treat iron/B12/folate deficiency anemia
- Optimize cardiac and pulmonary function
 - Acute normovolemic hemodilution
- Postoperative
 - Avoid unnecessary RBC transfusion



Optimizing Coagulopathy⁸

- Preoperative
 - Algorithm for patients on anticoagulation or anti-platelet medication
- Management of bleeding patients
 - Body temp > 36C
 - pH > 7.2
 - Hemorrhage monitoring (e.g. viscoelastic tests and/or hemoglobin, platelet count, coags including fibrinogen levels)
- Protocols for administration of blood components, factor concentrates, and antifibrinolytic agents
- Antifibrinolytics for cardiac, ortho, obstetric hemorrhage, massive hemorrhage surgeries
- Uremic platelet dysfunction (e.g. di-deoxy arginine vasopressin, DDAVP)



Blood Conservation Strategies⁸

- Minimize diagnostic blood loss
 - Reduced tube size
 - Fewer draws
- Surgical blood loss
 - “Close attention”
 - Minimally invasive techniques
 - Cell salvage



Optimal Blood Use with Patient-Centered Decision Making

- Informed consent
- Transfusion plan with thresholds based on risk
- Single unit transfusion policy
- Intelligent electronic ordering
- Ability to identify ordering provider
- Indication list (e.g. pocket card, posters)
- Documentation of the indication for each component



PBM-Related Metrics & Benchmarks^{9,10}

- Track anemia: preop, hospital-acquired, treated patients
- Use of antifibrinolytics, cell salvage
- Blood usage by dept or procedure or physician: # units/patient
 - Benchmarking
- Blood supply chain efficiency
 - Crossmatch : transfusion ratio (<1.7:1)
 - Issue : transfusion ratio
 - Wasted products

Physician	RBCs Transfused / Procedure
Smith	0.5
Jones	8
Doe	1
Adams	1.2



PBM-Related Metrics & Reporting

- Patient outcomes!
 - In-hospital mortality
 - Morbidity (infections, myocardial infarction, stroke, etc.)
 - Length-of-stay (LOS)
 - Hemoglobin (presurgical and postoperative)
 - Hemovigilance (e.g. transfusion reactions)
- Report to clinicians and hospital administration
 - Include cost savings, return on investment



References

1. NIS Related Reports [Internet]. [cited 2018 May 29]. Available from: <https://www.hcup-us.ahrq.gov/db/nation/nis/nisrelatedreports.jsp>
2. Proceedings from the National Summit on Overuse [Internet]. [cited 2018 Oct 29]. Available from: http://www.jointcommission.org/overuse_summit/
3. Shander A, Bracey AW, Goodnough LT, Gross I, Hassan NE, Ozawa S, et al. Patient Blood Management as Standard of Care. *Anesth Analg*. 2016;123:1051–3.
4. Ellingson KD, Sapiano MRP, Haass KA, Savinkina AA, Baker ML, Chung K-W, et al. Continued decline in blood collection and transfusion in the United States–2015. *Transfusion*. 2017;57:1588–98.
5. Mueller MM, Van Remoortel H, Meybohm P, Aranko K, Aubron C, Burger R, et al. Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. *JAMA*. 2019;321:983–97.
6. Hibbs SP, Nielsen ND, Brunskill S, Doree C, Yazer MH, Kaufman RM, et al. The impact of electronic decision support on transfusion practice: a systematic review. *Transfus Med Rev*. 2015;29:14–23.
7. Soril LJJ, Noseworthy TW, Dowsett LE, Memedovich K, Holitzki HM, Lorenzetti DL, et al. Behaviour modification interventions to optimise red blood cell transfusion practices: a systematic review and meta-analysis. *BMJ Open*. 2018;8:e019912.
8. Meybohm P, Richards T, Isbister J, Hofmann A, Shander A, Goodnough LT, et al. Patient Blood Management Bundles to Facilitate Implementation. *Transfusion Medicine Reviews*. 2017;31:62–71.
9. Frank SM, Resar LM, Rothschild JA, Dackiw EA, Savage WJ, Ness PM. A novel method of data analysis for utilization of red blood cell transfusion. *Transfusion*. 2013;53:3052-9.
10. Metcalf RA, White SK, Potter S, Barney R, Hunter C, White M, et al. The association of inpatient blood utilization and diagnosis-related group weight: implications for risk-adjusted benchmarking. *Transfusion*. 2019;59:2316-2323.

Disclosures/Potential Conflicts of Interest

Upon Pearl submission, the presenter completed the Clinical Chemistry disclosure form. Disclosures and/or potential conflicts of interest:

- **Employment or Leadership:** AABB Patient Blood Management Standards Committee Member (Volunteer)
- **Consultant or Advisory Role:** No disclosures
- **Stock Ownership:** No disclosures
- **Honoraria:** No disclosures
- **Research Funding:** ARUP Laboratories Research & Development Institute
- **Expert Testimony:** No disclosures
- **Patents:** No disclosures



Thank you for participating in this
Clinical Chemistry Trainee Council
Pearl of Laboratory Medicine.

Find our upcoming Pearls and other
Trainee Council information at
www.traineecouncil.org

Download the free *Clinical Chemistry* app
on iTunes today for additional content!

Follow us:

